Navigation Links
Octapharma Accepting Applications for Research Grants Through March 31
Date:2/4/2010

LACHEN, Switzerland and HOBOKEN, N.J., Feb. 4 /PRNewswire/ -- Octapharma USA will accept applications until March 31 for the Octapharma 25th Anniversary Grants Program, which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immunotherapy, intensive care and emergency medicine. Applications will be reviewed in April.

Octapharma AG, one of the largest plasma products manufacturers in the world, launched the grants program last year in celebration of the biopharmaceutical company's 25th anniversary. The company's first ever grants program is only available to researchers based in the United States and is administered by Octapharma USA, the Swiss company's rapidly-growing U.S. subsidiary.

"The grants program has been very well-received and we expect to be announcing our first recipient shortly," said Octapharma USA President Flemming Nielsen. "The U.S. market is very important to Octapharma and the grants program is just one way that we demonstrate our commitment. Our vision of providing patients with the safest, highest quality products available is stronger than ever."

Grant applications are accepted online only at www.octapharmagrants.com.  All grant requests will be evaluated by the Octapharma Grants Committee in April and grant recipients will be announced shortly afterward. Please visit www.octapharmagrants.com for a complete description of the grants program, including the application and review process.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma is one of the largest plasma products manufacturers in the world and has been committed to patient care and medical innovation for over 25 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam® (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's albumin (Human) is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of von Willebrand disease (VWD) and granted orphan drug exclusivity. Octapharma employs over 3,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com.

SOURCE Octapharma USA

RELATED LINKS
http://www.octapharma.com/USA/?&agree=yes

'/>"/>

SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Octapharma AG Announces Second Quarter 2009 Results and Mid Term Outlook of the Market
2. First Pharmaceutical Company Comes to Hoboken, NJ: Swiss-Based Octapharma to Move U.S. Headquarters to SJP Properties Waterfront Corporate Center II
3. CCMC Accepting Applications for Voluntary Service on its Board of Commissioners
4. Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery
5. Sleep HealthCenters Now Accepting Students for A-STEP Sleep Technologist Program
6. Lupus Foundation of America Accepting Letters of Intent for Research Grants on Adult Stem Cell Research and Health-Related Quality of Life in Pediatric Lupus
7. Nielsen Announces First-Ever CLIO Healthcare Awards Now Accepting Entries
8. ASTRO Accepting Survivor Circle Grant Applications
9. Prix Galien USA Now Accepting Nominations for Premiere Biopharmaceutical Industry Award
10. CCMC Accepting Applications for Second Annual Patricia McCollom Scholarship Through Aug. 1
11. Pittsburgh Day Spa Welcomes Dermatologist, Ana C. Busquets, MD, FAAD And Is Accepting New Patients In Upper St. Clair And Cranberry Locations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek ... Dr. Murthy explains how he was inspired to practice medicine at an early age ... is about more than making diagnoses and prescribing medicine,” he states. “It is about ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Sourced from ... has some unique properties including its unmatched natural purity of just 6 ppm TDS ... and crisp. , Nothing Water has been available in several ShopRite and FoodTown stores ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is ... create versatile lower third titles with just a few clicks of the mouse," said ... includes 30 lower third animations. Choose from various styles with accented animations, rigid boxes, ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... On Thursday, the NASDAQ Composite ended the trading ... edged 0.36% higher, to finish at 19,191.93; and the S&P ... as six out of nine sectors ended the day in ... Services equities: Myriad Genetics Inc. (NASDAQ: MYGN ), ... Inc. (NASDAQ: INCR ), and La Quinta Holdings ...
(Date:12/2/2016)... to announce that 12 scientific abstracts have been accepted for ... Society (AES) Annual Meeting, which takes place from 2-6 December ... Data being presented include posters further describing ... CV and BRIVIACT ® (brivaracetam) CV. 2,3,4,6,8 Presentations ... union of epilepsy care and antiepileptic drugs in the U.S. ...
(Date:11/30/2016)... DUBLIN , Nov 30, 2016 ... "US Market Overview for Neuromodulation, Neurovascular, Neurosurgical and Monitoring ... ... The full report suite on ... cerebrospinal fluid external drainage systems, intracranial pressure monitoring devices, detachable ...
Breaking Medicine Technology: